
Acta Pharmaceutica Sinica B, Journal Year: 2025, Volume and Issue: unknown
Published: April 1, 2025
Language: Английский
Acta Pharmaceutica Sinica B, Journal Year: 2025, Volume and Issue: unknown
Published: April 1, 2025
Language: Английский
Chemical Reviews, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 27, 2025
Nanozymes have shown significant potential in cancer catalytic therapy by strategically catalyzing tumor-associated substances and metabolites into toxic reactive oxygen species (ROS) situ, thereby inducing oxidative stress promoting cell death. However, within the complex tumor microenvironment (TME), rational design of nanozymes factors like activity, reaction substrates, TME itself significantly influence efficiency ROS generation. To address these limitations, recent research has focused on exploring that affect activity developing nanozyme-based cascade systems, which can trigger two or more processes tumors, producing therapeutic achieving efficient stable with minimal side effects. This area remarkable progress. Perspective provides a comprehensive overview nanozymes, covering their classification fundamentals. The regulation nanozyme strategies are discussed detail. Furthermore, representative paradigms for successful construction systems treatment summarized focus revealing underlying mechanisms. Finally, we current challenges future prospects development biomedical applications.
Language: Английский
Citations
3International Journal of Nanomedicine, Journal Year: 2025, Volume and Issue: Volume 20, P. 2969 - 2990
Published: March 1, 2025
Introduction: Ovarian cancer is a malignant tumor that arises in the female reproductive system and associated with very high mortality rate. This primarily due to highly invasive nature of metastasis recurrence. Transforming immune environment from an immunosuppressive state anti-tumor through phenotypic transformation tumor-associated macrophages crucial for inhibiting growth, metastasis, recurrence ovarian cancer. Methods: A polymer micelle (RC-PH-Ms) containing paclitaxel (PTX) honokiol (HNK) was designed based on expression reactive oxygen species microenvironment. Once micelles are actively targeted microenvironment characterized by elevated levels species, responsive bond cleaved, thereby exposing secondary targeting ligand C7R. The released PTX HNK facilitate relevant M2 phenotype M1 phenotype, which turn inhibits invasion inhibit angiogenesis reduce Results: effects RC-PH-Ms modulating vascularization were investigated both vivo vitro. Conclusion: can significantly cancer, provides new perspective clinical treatment. Keywords: recrudescence, immunotherapy,
Language: Английский
Citations
0Coordination Chemistry Reviews, Journal Year: 2025, Volume and Issue: 535, P. 216608 - 216608
Published: March 27, 2025
Language: Английский
Citations
0Journal of Nanobiotechnology, Journal Year: 2025, Volume and Issue: 23(1)
Published: April 4, 2025
Nanocatalysis coupled with photothermal therapy is a potent anti-cancer approach, yet its clinical utility limited by low concentration of tumor substrate, redox interference, and risks overheating normal tissues. Herein, we propose an innovative closed-loop nanozyme approach that leverages the synergistic effects catalytic mild (mPTT) to address aforementioned challenges. The strategy features folic acid-functionalized iron single-atom catalyst (FeNC-FA), designed exhibit exceptional multienzymatic capabilities optimal response. In system, engineered FeNC-FA capable inducing reactive oxygen species (ROS) storm depleting glutathione (GSH) in specific microenvironment (TME) initiate ferroptosis. Concurrently, accumulation ROS effectively cleaves heat shock proteins (HSPs), thereby enhancing mPTT. An intriguing aspect increased temperature within TME further facilitates conversion H2O2 O2, alleviating hypoxia providing positive feedback circuit boost therapy. Additionally, advanced photoacoustic (PA) imaging allow for self-monitoring their at sites, guiding mPTT process. Taken together, it provides PA image-guided, mutually reinforced both vitro vivo. This targeted holds great promise personalized medicine applications.
Language: Английский
Citations
0Acta Pharmaceutica Sinica B, Journal Year: 2025, Volume and Issue: unknown
Published: April 1, 2025
Language: Английский
Citations
0